Shikari® (Q-RAN) Ranibizumab ELISA

Enzyme immunoassay for the quantitative determination of Ranibizumab (Lucentis®) in serum and plasma.

This kit has been especially developed for the quantitative determination of ranibizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

Ranibizumab Drug Bank Accession Number is DB01270.

Ranibizumab is a recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema. Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody directed against human VEGF-A.5 Ranibizumab binds to VEGF-A with high affinity as well as its biologically active forms, such as VEGF165, VEGF121, and VEGF110. Ranibizumab binds to the receptor-binding site of VEGF-A, preventing it from binding to its receptors - VEGFR1 and VEGFR2 - that are expressed on the surface of endothelial cells. Ranibizumab thereby attenuates endothelial cell proliferation, vascular leakage, and new blood vessel formation. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary. 

All SHIKARI® ELISA kits are suitable for biosimilar work.

All SHIKARI® ELISA kits are produced under ISO 13485 quality system.

Research Use Only (RUO)

For technical inquiry, IFU and other relevant documents please contact techsupport@matriksbiotek.com